

1 **SI APPENDIX**

2 **SUPPLEMENTAL FIGURES**

3

4

5

6

7

8

9


10

11

12

13

14



15 **Figure S1: Effects of TDF and TAF on EBV DNA copies during latency**

16 (A) HH514-16 cells were grown in the absence of butyrate for 96 hours and treated with the

17 tenofovir prodrugs TDF and TAF, or the established anti-herpesviral drugs ACV and GCV. EBV

18 copies per genome were measured by qPCR after 96 hours of treatment at a 50μM dose. Results

19 were analyzed from 3 independent experiments, each value shown. One-way ANOVA was


20 performed ($p > 0.05$). (B) Viability was measured by trypan blue exclusion after 96 hours. Results

21 were analyzed from 4 independent experiments, each value shown. One-way ANOVA ($p < 0.05$)

22 was followed by multiple hypothesis testing between no drug and each condition. Statistical

23 significance is highlighted by P values as follows: *** $P < 0.001$.

24
25
26
27
28
29
30
31
32
33
34
35
36
37
38



39 **Figure S2: Effects of butyrate and drug treatment on the number of cells after 96 hours**

40 HH514-16 cells were treated with the tenofovir prodrugs TDF and TAF, or the established anti-
41 herpesviral drugs ACV and GCV. Cell count per mL was measured after 96 hours of treatment at
42 a 50µM dose. Results were analyzed from 5 independent experiments, each value shown. (B) One-
43 way ANOVA ($p < 0.05$) was followed by multiple hypothesis testing between butyrate and each
44 condition. Statistical significance is highlighted by P values as follows: * $P < 0.05$; ** $P < 0.01$

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67




Figure S3: Effect of TDF and TAF dose on the number of viable cells in latency after 96 hours

HH514-16 cells were treated with TDF or TAF at indicated doses in the absence of butyrate. Total cell viability was measured by an ATP-dependent luminescence assay after 96 hours of treatment, which is dependent on both cell proliferation and percent viability. Luminescence was normalized using the signal from untreated samples (no cytotoxicity) and the signal from samples treated with 10μM podophyllotoxin (max. cytotoxicity). Results were analyzed from 3 independent experiments. Values shown represent mean and SD. A dose-response curve was fit by linear regression analysis.

68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87




Figure S4: Effects of ACV and GCV on expression of early and late lytic viral genes

(A) HH514-16 cells were induced with 3mM butyrate and treated with ACV[62.5μM], GCV[5μM], or no drug. Total RNA was collected at 72 hours and used to measure the expression of six early and (B) six late lytic genes by RT-qPCR. Gene expression was normalized to the housekeeping gene HPRT1. Each column represents the mean and SD obtained from 3 independent experiments.

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109




Figure S5: ACV-TP effects on the HSV-1 DNA polymerase

The HSV-1 polymerase subunits (UL30 and UL42) were cloned into pcDNA3.1+ vector and produced using a transcription/translation system in Rabbit reticulocyte lysates. (A) *In vitro* polymerase assays were performed by measuring the incorporation of $[^3\text{H}]$ dGTP into activated calf thymus DNA during a 40 min reaction followed by DEAE filter-binding and scintillation counting. Each column represents the mean and SD of counts per minute (cpm) obtained from 3 independent experiments. (B) ACV-TP was added to the reaction in the presence of 1 μM $[^3\text{H}]$ dGTP from 0-50 μM . Every 5 minutes, aliquots were removed and quenched with EDTA. Counts per minute were normalized to maximum counts obtained at 40 min. Results were analyzed from 2 independent experiments, each value shown. (C) Dose-response curves were generated from mean inhibition of dGTP incorporation at 40 min by five-parameter logistic regression analysis.

110

111

112

113

114

115

116


117

118

119 **Figure S6: HH514-16 cells express cathepsin A**

120 HH514-16 cells were induced with 3mM butyrate. Total protein was collected at 72 hours and

121 stained for cathepsin A, Ea-D, or β -actin by western blot.



122 **Table S1: Primers and probes for qPCR**

Gene	Primer 1 (5'-3')	Primer 2 (5'-3')	Probe (FAM/ZEN/Iowa Black FQ)
BALF2	CTACCAGGAGGGAGAACTACAT	GTACAGGCTTGAGAGCTTAGTG	TCCTCAACACCTACCACAAGACCCTA
BALF5	CGGAAGCCCTCTGGACTTC	CCCTGTTTATCCGATGGAATG	TGTACACGCACGAGAAATGCGCC
BGLF4	GGCTGGTCTGACTGATTATG	TCTGGCAATAGAGGCGATAGA	ATGCTGGATGTGCGGCTAAAGTCT
BaRF1	GATTCTTGTGTTCTGCTGATTG	GAGCAGCTCATCCCTACTTATG	TGGCATCTGCCTGGCCAATAACTA
BBLF2/3	CAGTCCTCCTCAGATCTCAAAC	CTGCGGTCTGGGTAACATTAT	AATGATGGAAACACCCGCGGAGA
BMR1	TTTACAGGTCTGGCATCATAGC	CTTCGGAGGCGTGGTTAAATA	AACACTAAGATCCAACGGCAGGTCC
BILF2	GGGAAGAAGACGACCAATACC	TTGTGGTGTGGGAGACTAATG	ACCCTCACTCAGCGTATGCATCTT
BcLF1	GTGGAGGCATGGATCGTAAA	TTGAGGCTGTTTAGGGTATGG	AATGCTCTCAAGGTTCTCTGTCACCC
BDLF1	AAATGGTGCCGGATGAGATAG	GATGCCAAAGACTGTAGGTAGG	TGACCTGTCAGTGGCGGATGATTT
BDLF2	GTGTCCGACCAATCCATTCT	ATGGCTGTCCGTGTTGTT	TATCCCGGCCGTGGTCATTAACAA
BVRF1	CCCAGTATGCAGTCTCAATCTC	GGTACCCACTGGTTGATGTT	ACGCTGCTTGGTAATCTGTACGGG
BVRF2	CTTCTTTGACCACGTGTCTATCT	GACGGTTCAGGTCACTAAAG	ACGGCAGTCTACGGTACAGACCTT
HPRT1	TTGTTGATAGGATATGCCCTTGA	GCGATGTCAATAGGACTCCAG	AGCCTAAGATGAGAGTTCAAGTTGAGTTTG

124 SUPPLEMENTAL METHODS

125

126 **Quantification of EBV copy number by qPCR**

127 Cells were centrifuged at 500xg for 3 min and washed once with PBS. Genomic DNA was
128 extracted using the Qiagen DNeasy Blood & Tissue Kit (Qiagen) and subjected to qPCR. A 20 μ L
129 reaction was set up with 250ng genomic DNA. The PCR mix contained 1x PrimeTime qPCR
130 Master Mix (Integrated DNA Technologies), 500 nM each primer, and 250 nM probe.

131 Primers and fluorescent probes (5'FAM/ZEN/3'IBFQ) for the BALF5 gene of EBV and GAPDH
132 (Integrated DNA Technologies) are listed below:

133 BALF5 primers: 5'-CGGAAGCCCTCTGGACTTC-3', 5'-CCCTGTTTATCCGATGGAATG-
134 3', BALF5 probe: 5'-TGTACACGCACGAGAAATGCGCC-3', GAPDH primers: 5'-
135 ACATCACCCCTCTACCTCC-3', 5'-CTCCCACCTTTCTCATCCAAG-3', GAPDH probe: 5'-
136 AAAGCCAGTCCCCAGAACCCC-3'.

137 The following cycling conditions were used: 95°C for 10 min followed by 40 cycles with 95°C for
138 15s and 60°C for 45s carried out on a LightCycler 480 system (Roche Diagnostics). GAPDH was
139 used as an internal standard. The calculation of the relative amounts of BALF5 DNA compared to
140 GAPDH DNA was performed using the $2^{-\Delta\Delta C_p}$ method using the C_p (second derivative maximum)
141 calculated by the LightCycler software. Each experiment was performed with three biological
142 replicates. To calculate the absolute number of EBV copies, the EBV BALF5 gene was cloned by
143 PCR from HH514-16 genomic DNA into pcDNA3.1+ vector. Absolute EBV DNA copy number
144 was calculated from a standard curve generated by serial dilutions of pcDNA3.1-BALF5 added to
145 human genomic DNA extracted from the EBV-negative A549 cancer cell line (ATCC).

146

147 **Measurement of cell viability by trypan blue**

148 Cells (seeded at an initial concentration of 4×10^5 cells/mL), were examined at timepoints and drug
149 concentrations indicated in the text. Viability was measured by trypan blue exclusion using a 1:1
150 mixture of a cell suspension with 0.4% trypan blue in PBS, and quantified using an Auto T4
151 Cellometer Cell Counter (Nexcelom Biosciences).

152

153 **Luminescent total cell viability assay**

154 Cells were seeded at a density of 4×10^5 cells/mL in a volume of 200 μ L in 96 well plates. After 96
155 hours, the cells were mixed with CellTiterGlo reagent (Promega) according to manufacturer's
156 instructions, and luminescence was quantified using a Varioskan Flash plate reader (Thermo
157 Fisher). Luminescence was normalized using the signal from untreated samples (no cytotoxicity)
158 and the signal from samples treated with 10 μ M podophyllotoxin (Sigma) (max. cytotoxicity).

159

160 **Dose-response curves for inhibition of EBV DNA replication and calculation of IC₅₀**

161 Dose-response curves for inhibition of EBV lytic DNA replication were fit by four-parameter
162 logistic regression analysis using the Prism 8 software (GraphPad), and IC₅₀ measurements were
163 calculated by the software using best-fit values.

164

165 **Calculation of effective inhibitory concentration of TFV-DP in PBMCs from *in vitro***
166 **polymerase assays**

167 Dose-response curves for inhibition of EBV lytic DNA replication were fit by five-parameter
168 logistic regression analysis using the Prism 8 software (GraphPad) with top and bottom plateaus
169 specified as 100 and 0, respectively. EC₅₀ measurements and Hill slope were calculated by the

170 software using best-fit values. The following equation derived from the Hill equation was used to
171 calculate EC_F , the concentration required to produce F, the percent response. Here, EC_{50} is the
172 concentration that leads to 50% maximal response, and H is the Hill slope:

$$173 \quad EC_F = \left(\frac{F}{100 - F} \right)^{\sqrt{H}} \times EC_{50}$$

174

175 **Western blotting for early antigen and cathepsin A expression**

176 Cells were centrifuged at 500xg for 3 min and washed once with ice-cold PBS. Cells were lysed
177 in RIPA buffer supplemented with protease inhibitor tablets (Sigma) and phosphatase inhibitor
178 cocktail (Thermo Fisher), on ice for 30 minutes. Cell lysates were centrifuged at 14,000xg for 30
179 min at 4°C to remove debris, and supernatants were assayed for protein concentration by BCA
180 assay to normalize for total protein. Samples were boiled in 1X NuPAGE LDS sample buffer
181 (Thermo Fisher) with 2-mercaptoethanol at a final concentration of 2.5% for 10 minutes and
182 loaded in a NuPAGE 10% Bis-Tris Protein Gel (Thermo Fisher). The gel was transferred to a
183 nitrocellulose membrane using the iBlot gel transfer device (Thermo Fisher). Membranes were
184 blocked for 30 min at room temperature in PBS + 0.1% Tween-20 (PBS-T) + 5% nonfat dry milk
185 (Bio-Rad) and incubated with primary antibodies in with PBS-T with 10% StartingBlock blocking
186 buffer (Thermo Fisher) overnight. Membranes were then washed with PBS-T for 15 min,
187 incubated with HRP-linked secondary antibodies (Cell Signaling) for 2 hours at room temperature,
188 washed in PBS-T for 30 minutes, and developed using 1 Step Ultra TMB Blotting Solution
189 (Thermo Fisher). Blots were imaged with the Bio-Rad ChemiDoc XRS imaging system.
190 Antibodies were obtained and used at the following dilutions: mouse anti-EBV EA-D (Thermo
191 Fisher) at 1:100, rabbit anti- β -actin (Cell Signaling) at 1:1000, mouse anti-human CTSA (R&D

192 systems) at 1µg/mL, anti-rabbit IgG HRP (Cell Signaling) at 1:1000, and anti-mouse IgG HRP
193 (Cell Signaling) at 1:1000.

194

195 **Quantitative RT-PCR for measurement of gene expression**

196 Total RNA was isolated from HH514-16 cells using the RNeasy Mini Kit (Qiagen). RNA (2.5µg)
197 was used for synthesis of cDNA using the SuperScript IV VILO Master Mix with ezDNase kit
198 (Thermo Fisher), and cDNA was then used at a 1:10 dilution for qPCR. Each reaction contained
199 1x PrimeTime qPCR Master Mix (Integrated DNA Technologies), 500 nM each primer, and
200 250nM fluorescent (5'FAM/ZEN/3'IBFQ) probe. The following cycling conditions were used:
201 95°C for 10 min followed by 45 cycles with 95°C for 15s and 60°C for 45s carried out on a
202 LightCycler 480 system (Roche Diagnostics). HPRT1 was used as a housekeeping gene for
203 normalization of gene expression. The calculation of relative gene expression was done by the 2⁻
204 $\Delta\Delta C_t$ method using the C_p (second derivative maximum) calculated by the LightCycler software.
205 Primers and fluorescent probes for gene expression (IDT) are listed in supplemental Table 1.

206

207 **Recombinant HSV-1 DNA polymerase assays**

208 Assays were performed as described for EBV DNA polymerase assays except that the UL30 and
209 UL42 subunits were cloned by PCR from HSV-1 genomic DNA, MacIntyre strain (ATCC) into
210 pcDNA3.1+ . For drug-triphosphate testing, only the UL30 protein was used for polymerase assays
211 since the UL42 protein was dispensable for activity. After desalting, samples were diluted to
212 normalize for polymerase activity to that obtained with the EBV polymerase.

213

214 **Pre-treatment of cells in latency prior to induction of viral lytic DNA replication**

215 Cells were seeded at an initial concentration of 4×10^5 cells/mL and incubated for 48 hours in
216 media without butyrate. After this time, drugs were added at the indicated concentrations, and cells
217 were incubated for an additional 24 hours. Cells were then centrifuged at 500xg for 3 min and
218 washed five times with fresh media without drug. After the final wash, cells were resuspended at
219 a concentration of 4×10^5 cells/mL in media containing 3mM butyrate. To remove supernatant for
220 drug testing, half of the cell suspension from this step was re-centrifuged, and the butyrate-
221 containing supernatant was filtered using a $0.2 \mu\text{M}$ cellulose acetate syringe filter. Cells previously
222 unexposed to drug were resuspended in this post-wash supernatant at a concentration of 4×10^5
223 cells/mL. Genomic DNA was removed for measurements of EBV copy number every 24 hours.

224

225 **Statistical Analysis**

226 As indicated in text, a Brown-Forsythe and Welch ANOVA for unequal variances was initially
227 used. Multiple hypothesis testing was then conducted, with correction for multiple testing using
228 the Prism 8 software (GraphPad).